Robert Bissonnette, MD: Discussing Recent Data on Topical Therapies for Atopic Dermatitis

During this interview, Robert Bissonnette, MD, Chief Executive Officer and medical director of Innovaderm Research, spoke with the HCPLive editorial team about 4 topical treatment options for atopic dermatitis (AD) covered in his presentation titled ‘Topical therapy revolution.’

The talk was presented at the Revolutionizing Atopic Dermatitis (RAD) 2024 Annual Meeting in Chicago. Bissonnette noted his interest prior to the conference talk in the subject discussed in his presentation.

“With some of these drugs, I was privileged enough to be the first physician to treat patients,” Bissonnette explained. “So I have a strong interest in topical therapy for atopic dermatitis and other skin diseases.”

Bissonnette was first asked about which treatment options in the topical space that he had discussed in his talk.

“I covered 4 drugs,” Bissonnette said. “I covered what's new with crisaborole and what's new with topical ruxolitinib. These 2 drugs are currently approved topically for the treatment of atopic dermatitis in the US. I also covered some new data on roflumilast and some new data from tapinarof well, which are not yet approved for atopic dermatitis.”

Bissonnette first discussed the utilization of crisaborole in recent research, highlighting the studies’ findings in the use of this topical option.

“The studies showed that in a proportion of patients, not the majority of patients, when you gain control with twice a day treatment, if you decrease to once a day, you still maintain control,” Bissonnette explained.

He also highlighted ruxolitinib’s newer research on use among younger populations, specifically ages 2 - 11 years.

“That trial showed that the efficacy and the safety in that younger population was as good in the population of adolescent and adult patients,” Bissonnette said.

For additional information on these therapies for eczema, view the full interview posted above.

The quotes contained in this summary were edited for clarity.